This comprehensive review of obesity medications reveals that GLP-1 receptor agonists like semaglutide and newer multiagonist therapies like tirzepatide produce beneficial effects across 12 major disease systems, including cardiovascular disease, kidney disease, liver disease, sleep apnea, depression, and neurodegenerative conditions. Critically, many of these benefits appear independent of weight loss itself, suggesting direct therapeutic mechanisms beyond metabolic improvement. The paradigm shift here is profound: obesity medications are transitioning from simple weight-loss tools to broad-spectrum disease-modifying therapies. This represents a fundamental reconceptualization of how we approach chronic disease management in an aging population. The weight-independent effects particularly matter for longevity, as they suggest these drugs could benefit metabolically healthy individuals or those with normal weight but elevated disease risk. However, the review synthesizes existing trial data rather than presenting new clinical evidence, and long-term safety profiles for these pleiotropic effects remain under investigation. This positions GLP-1-based therapies as potential cornerstone interventions for healthy aging, though optimal patient selection and dosing strategies for non-obesity indications require further research.